Cortechs.ai | Prediction of amyloid positivity using automated segmentation
Cortechs.ai | Prediction of amyloid positivity using automated segmentation
Contact

Prediction of amyloid positivity using automated segmentation

  • Category: Published research
  • Disease: Mild cognitive impairment

Prediction of amyloid positivity in mild cognitive impairment using fully automated brain segmentation software

The objective of this study was to assess the predictive ability of regional volume information provided by fully automated brain segmentation software for cerebral amyloid positivity in mild cognitive impairment (MCI). (2020).

[button]Download[/button]

  • Topic: Published research

More Resources

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 3 mins

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 2 mins

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 6 mins

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 5 mins

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 2 mins

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 3 mins

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

View our insights
Cortechs.ai | Prediction of amyloid positivity using automated segmentation
Cortechs.ai | Prediction of amyloid positivity using automated segmentation

Empowering precision

and clarity in patient care

5060 Shoreham Place,
Ste 240, San Diego, CA 92122

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • Solutions
  • © Cortechs.ai 2024
Scroll to Top